U.S. Markets closed

Nektar Therapeutics (NKTR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
16.51+0.13 (+0.79%)
At close: 4:00PM EDT
16.68 +0.17 (1.03%)
After hours: 06:54PM EDT

Nektar Therapeutics

455 Mission Bay Boulevard South
San Francisco, CA 94158
United States
415 482 5300

Full Time Employees718

Key Executives

NameTitlePayExercisedYear Born
Mr. Howard W. RobinCEO, Pres & Director2.24MN/A1953
Mr. Gilbert M. LabrucherieSr. VP, CFO & COO1.54MN/A1972
Mr. Mark A. WilsonSr. VP, Gen. Counsel & Sec.780.49kN/A1972
Dr. Jonathan ZalevskyChief R&D Officer1.19MN/A1975
Mr. John P. NorthcottSr. VP & Chief Commercial Officer1.16MN/A1978
Ms. Jillian B. ThomsenSr. VP of Fin. & Chief Accounting OfficerN/AN/A1966
Ms. Jennifer RuddockSr. VP of Strategy & Corp. AffairsN/AN/AN/A
Dr. Mary TagliaferriSr. VP & Exec. Clinical FellowN/AN/A1966
Dr. Brian L. KotzinInterim Chief Medical Officer & Head of Devel.N/AN/A1949
Dr. Kevin BrodbeckSr. VP of ManufacturingN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Nektar Therapeutics operates as a biopharmaceutical company. The company researches and develops pipeline of investigational medicines in oncology, immunology, and virology, as well as a portfolio of approved partnered medicines. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of non-small cell lung cancer and immuno-oncology; and phase 1B clinical trial to treat COVID-19.It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat locally advanced or metastatic solid tumor malignancies, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California with additional operations in Huntsville, Alabama and Hyderabad, India.

Corporate Governance

Nektar Therapeutics’s ISS Governance QualityScore as of June 1, 2021 is 3. The pillar scores are Audit: 6; Board: 4; Shareholder Rights: 3; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.